x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012086
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat, Monkey |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Asp54 of human GOT2 protein. Antibodies are purified by peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | GOT2 |
| UniProt No. | P00505 |
| Gene ID | 2806 |
| Gene Description | Glutamate oxaloacetate transaminase 2, a mitochondrial enzyme, catalyzes the conversion of oxaloacetate to aspartate. Studies show that the metabolite pyridoxal phosphate is selectively required by acute myeloid leukemia. PLP-dependent GOT2 selectively sustains leukemic cell proliferation. Depletion of GOT2 suppresses the proliferation of acute myeloid leukemia cells. In addition, mouse hematopoietic stem cells are dependent on cell-autonomous aspartate synthesis. Got2 deletion leads to decreased levels of aspartate and reduced function of hematopoietic stem cells. Furthermore, GOT2-dependent aspartate synthesis is also necessary for protein and collagen biosynthesis in chondrocytes and is critical for chondrocyte proliferation and growth. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
